Structural basis of measles virus polymerase inhibition by nonnucleoside inhibitor ERDRP-0519
Dong Wang, Fan Bu, Ge Yang, Bin Liu

TL;DR
Scientists discovered how a drug called ERDRP-0519 blocks the measles virus by binding to a specific part of its polymerase enzyme.
Contribution
The study reveals the structural mechanism of ERDRP-0519 inhibition and identifies a unique binding pocket in the MeV polymerase.
Findings
ERDRP-0519 binds to a unique pocket in the RdRp palm subdomain of the MeV polymerase.
The compound overlaps with the catalytic GDN motif, explaining resistance mutations like W671.
The findings provide a structural basis for developing improved antiviral drugs against Morbilliviruses.
Abstract
ERDRP-0519 is a potent nonnucleoside inhibitor active against measles virus (MeV) and other Morbilliviruses. Here we report cryo-EM structures of the compound bound to MeV polymerase complexes at 2.73 Å and 2.48 Å resolution, revealing a unique binding pocket in the RdRp palm subdomain that overlaps the catalytic GDN motif. These findings clarify the basis of resistance mutations, including W671, and provide a foundation for designing next-generation Paramyxovirus antivirals. ERDRP-0519 is a potent nonnucleoside inhibitor of Morbilliviruses. In this work, authors solve cryo-EM structures that reveal ERDRP-0519 bound to measles RNA polymerase in a unique RdRp palm pocket, clarifying resistance mutations and guiding next-generation antivirals.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVirology and Viral Diseases · HIV Research and Treatment · vaccines and immunoinformatics approaches
